Nouscom secures additional funding from Angelini Ventures

Based in Basel, Nouscom is a clinical stage immune-oncology company developing off-the-shelf and personalized cancer vaccines based on its proprietary viral vector platform, which has the capacity to encode for large payloads of neoantigens or other immunomodulators. 

The additional funding from the series C extension round will help fuel the further development and expansion of its drug candidates to achieve multiple clinical value catalysts. This includes the readout from its ongoing randomized Phase 2 clinical trial for NOUS-209, an off-the-shelf cancer immunotherapy for the treatment of MSI solid tumors in combination with pembrolizumab, the completion and progression of Phase 1b study of NOUS-209 in Lynch Syndrome (LS) carriers investigating the potential to intercept, prevent or delay cancer in high-risk individuals. The funds will also accelerate the Phase 1b study completion for NOUS-PEV in combination with a checkpoint inhibitor in patients with advanced melanoma and entry into randomized Phase 2 trials in 2024 in indications with high unmet medical needs.

Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions and ideas in BioTech and Digital Health, contributed €7 million, thereby joining a syndicate of top-tier international healthcare investors, including new investors: Andera Partners, Bpifrance (through its InnoBio 2 fund), M Ventures, Revelation Partners, Indaco Venture Partners, Panakès Partners, XGen Ventures; existing investors: 5AM Ventures, EQT Life Sciences, Versant Ventures; and other undisclosed investors. The investment brings the total amount raised by Nouscom in its oversubscribed Series C round – first announced in November 2023 – to €75.8 million.

(Press release/RAN)